{"nctId":"NCT00624286","briefTitle":"Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2008-02"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":416,"armGroups":[{"label":"Indacaterol 150 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 150 μg"]},{"label":"Placebo to indacaterol","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to indacaterol"]}],"interventions":[{"name":"Indacaterol 150 μg","otherNames":[]},{"name":"Placebo to indacaterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n• Male or female patients aged 40 years or over with moderate to severe chronic obstructive pulmonary disease (COPD) plus\n\n* 20 pack-year smoking history\n* Signed informed consent\n* Post-bronchodilator forced expiratory volume in 1 second )FEV1) ≥ 30% and \\< 80% predicted FEV1/FVC (forced vital capacity) \\< 70%\n\nExclusion Criteria include:\n\n* History of asthma\n* Prior exposure to indacaterol\n* Active cancer or history of cancer\n* Patients with concomitant pulmonary disease\n* Patients with diabetes Type I or uncontrolled diabetes Type II\n* Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at screening or randomization is prolonged\n* Patients unable to successfully use a dry-powder inhaler device or perform spirometry measurements\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85)","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":"0.018"},{"groupId":"OG001","value":"1.35","spread":"0.019"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose on Day 2","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 30 minutes post-dose of salbutamol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":"0.014"},{"groupId":"OG001","value":"1.38","spread":"0.014"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":211},"commonTop":["Chronic obstructive pulmonary disease","Cough"]}}}